CTOs on the Move

CARsgen

www.carsgen.com

 
CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. Our vision is to become a global biopharmaceutical leader that brings innovative ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.carsgen.com
  • 6575 West Loop South Suite 455
    Bellaire, TX USA 77401
  • Phone: 346.293.9392

Executives

Name Title Contact Details

Similar Companies

Anagenex

Discovering new medicines by combining ultra throughput biochemistry and machine learning.

Primorigen Biosciences

Primorigen Biosciences LLC is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Navitor Pharmaceuticals

Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The companys proprietary drug discovery platform targets mTORC1, which responds to and integrates the cells response to nutrient availability and plays a key role in protein synthesis and cellular growth. Navitors therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activity to address a wide range of diseases, including metabolic, neurodegenerative, autoimmune and musculoskeletal diseases, as well as several rare disorders. The companys founding intellectual property is based on the groundbreaking discoveries related to the mTORC1 pathway and nutrient signaling mechanisms by Dr. David Sabatini at The Whitehead Institute for Biomedical Research. The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, Johnson and Johnson Development Corporation, SR One and The Longevity Fund.

Orig3n

Founded in 2014, Boston based Orig3n exists at the intersection of biological science and emerging technology. Through our DNA tests and community events, we help people understand the links between their genes and how their minds and bodies work. Our research team uses cutting-edge cellular science to develop personalized therapies for repairing tissue damage and disease. Together with our community, we`re on a mission to accelerate the future of regenerative medicine.

Scioto Biosciences

Scioto Biosciences is a preclinical stage biotech company dedicated to innovative research and discovery in the field of microbiome therapeutics.